胰高血糖素样肽-1受体激动剂使用与青光眼风险降低相关
本研究利用保险索赔数据库开展回顾性队列研究,将1961例新启用GLP-1R激动剂的患者与4371例启用其他口服降糖药的患者进行1:3匹配。经逆概率治疗加权和多因素Cox回归调整后,GLP-1R激动剂暴露与新发青光眼诊断风险降低相关(HR 0.56,95%CI 0.36-0.89,p=0.01)。
要点
- GLP-1R激动剂队列青光眼新诊断率为0.51%,未暴露对照组为1.33%。
- 调整后GLP-1R暴露与新发青光眼风险降低相关,HR为0.56(95%CI 0.36-0.89,p=0.01)。
- 研究支持进一步探索GLP-1R激动剂用于青光眼预防。
核心结论
- GLP-1R激动剂使用与新发青光眼诊断风险显著降低相关。
- 研究结果支持进一步研究GLP-1R激动剂在青光眼预防中的应用。
研究设计与样本
- 回顾性队列研究,使用保险索赔数据库(Clinformatics Data Mart)。
- 新启用GLP-1R激动剂患者1961例,按1:3匹配至4371例启用其他类别口服降糖药的患者。
- 匹配因素包括年龄、性别、种族、活性降糖药物类别和索引日期年份。
- 采用逆概率治疗加权(IPTW)和多因素Cox比例风险回归模型分析。
主要发现
- IPTW后所有变量在组间均衡(标准化均数差<|0.1|)。
- 调整后GLP-1R暴露的 hazard ratio 为0.56(95%CI 0.36-0.89,p=0.01)。
关键数值与推荐
- 结局定义:新诊断的原发性开角型青光眼、青光眼疑似或低眼压性青光眼。
临床怎么用
- 对于使用GLP-1R激动剂的糖尿病患者,可能伴随青光眼风险降低,但需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIMS: Glucagon-like peptide-1 receptor (GLP-1R) agonists regulate blood glucose and are commonly used to treat type 2 diabetes mellitus. Recent work showed that treatment with the GLP-1R agonist NLY01 decreased retinal neuroinflammation and glial activation to rescue retinal ganglion cells in a mouse model of glaucoma. In this study, we used an insurance claims database (Clinformatics Data Mart) to examine whether GLP-1R agonist exposure impacts glaucoma risk. METHODS: A retrospective cohort of patients who initiated a new GLP-1R agonist was 1:3 age, gender, race, classes of active diabetes medications and year of index date matched to patients who initiated a different class of oral diabetic medication. Inverse probability of treatment weighting (IPTW) was used within a multivariable Cox proportional hazard regression model to test the association between GLP-1R agonist exposure and a new diagnosis of primary open-angle glaucoma, glaucoma suspect or low-tension glaucoma. RESULTS: Cohorts were comprised of 1961 new users of GLP-1R agonists matched to 4371 unexposed controls. After IPTW, all variables were balanced (standard mean deviation <|0.1|) between cohorts. Ten (0.51%) new diagnoses of glaucoma were present in the GLP-1R agonist cohort compared with 58 (1.33%) in the unexposed controls. After adjustment, GLP-1R exposure conferred a reduced hazard of 0.56 (95% CI: 0.36 to 0.89, p=0.01), suggesting that GLP-1R agonists decrease the risk for glaucoma. CONCLUSIONS: GLP-1R agonist use was associated with a statistically significant hazard reduction for a new diagnosis of glaucoma. Our findings support further investigations into the use of GLP-1R agonists in glaucoma prevention.
引用
- Sterling J, Hua P, Dunaief JL, et al. Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma. Br J Ophthalmol. 2021. PMID: 34413054. doi:10.1136/bjophthalmol-2021-319232
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。